newsfilter
← Earnings
Earnings Releases·

Merck & Co., Inc. — Third Quarter 2026 Earnings Summary

Merck & Co., Inc. reported third-quarter 2026 worldwide sales of $18.1 billion, representing a 5% increase driven by strong performance in oncology and animal health. Key product sales included KEYTRUDA at $8.6 billion and WINREVAIR, which saw a 93% growth to $694 million. The company announced positive clinical data for several pipeline candidates, including sacituzumab tirumotecan and intismeran autogene, while raising its full-year 2026 sales outlook to a range of $66.8 billion to $67.3 billion. Non-GAAP earnings per share for the quarter were $2.49, reflecting a one-time charge related to a global license agreement with SciBrunch.

Company
MERCK & CO INC
Sector
Healthcare
Industry
Drug Manufacturers - General